Co-Diagnostics Inc (CODX) Q3 2024 Earnings Call Highlights: Navigating Revenue Decline and ... [Yahoo! Finance]
Co-Diagnostics, Inc. (CODX)
US:NASDAQ Investor Relations:
ir.codiagnostics.com/investor-relations
Company Research
Source: Yahoo! Finance
Product Revenue: $0.2 million in the third quarter of 2024. Gross Profit: $0.3 million, compared to $2.2 million in the prior year comparable period. Total Operating Expenses: $10.6 million, decreased from $11.1 million in the third quarter of 2023. Research and Development Expenses: $4.9 million, compared to $5.8 million in the prior year period. Income Before Taxes: Loss of $9.7 million, compared to a loss of $8.1 million in the prior year. Net Loss: $9.7 million or $0.32 per fully diluted share, compared to a net loss of $6.0 million or $0.20 per fully diluted share in the prior year. Adjusted EBITDA: Loss of $8.8 million, compared to a loss of $6.5 million in the prior year. Cash, Cash Equivalents, and Marketable Investment Securities: $37.7 million at the end of the quarter. Warning! GuruFocus has detected 5 Warning Signs with CODX. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcr
Show less
Read more
Impact Snapshot
Event Time:
CODX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CODX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CODX alerts
High impacting Co-Diagnostics, Inc. news events
Weekly update
A roundup of the hottest topics
CODX
News
- Global COVID-19 Diagnostic Market Report 2024 -2029: A New Very Large and Sustainable Market for Covid Related Diagnostics is Emerging [Yahoo! Finance]Yahoo! Finance
- Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility [Yahoo! Finance]Yahoo! Finance
- Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo FacilityPR Newswire
- Co-Diagnostics, Inc. (NASDAQ: CODX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.MarketBeat
- Co-Diagnostics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
CODX
Earnings
- 11/7/24 - Beat
CODX
Analyst Actions
- 11/11/24 - HC Wainwright
CODX
Sec Filings
- 11/25/24 - Form 4
- 11/25/24 - Form 4
- 11/25/24 - Form 4
- CODX's page on the SEC website